Journal article
Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis
Abstract
BACKGROUND: Rituximab is commonly used as a treatment for primary immune thrombocytopenia to induce and maintain remission. The benefit of adding rituximab to standard-of-care treatment is uncertain.
METHODS: We did a systematic review and meta-analysis of randomised controlled trials assessing the efficacy and safety of rituximab for treatment of adults with primary immune thrombocytopenia. We searched Medline, Embase, and the Cochrane …
Authors
Chugh S; Darvish-Kazem S; Lim W; Crowther MA; Ghanima W; Wang G; Heddle NM; Kelton JG; Arnold DM
Journal
The Lancet Haematology, Vol. 2, No. 2, pp. e75–e81
Publisher
Elsevier
Publication Date
February 2015
DOI
10.1016/s2352-3026(15)00003-4
ISSN
2352-3026